Subhallucinogenic Concentrations of Substituted Phenethylamines as a Novel Therapeutic Approach for Inflammatory and Neurological Disorders.
ACS medicinal chemistry letters July 13, 2023 DOI: 10.1021/acsmedchemlett.3c00220 via PubMed
Summary
AI-generated from the abstractA patent describes a method for treating inflammatory or neurological disorders by administering a composition containing a subhallucinogenic dose of a substituted phenethylamine, such as those from the 2C-X family (e.g., 2C-H, 2C-I, 2C-B, or 2C-E). The dose depends on the severity of chronic inflammation: 25 mg for mild, 50 mg for moderate, and 100 mg for severe cases. The method is intended for subjects in need of treatment.
Study at a glance
| Characteristics | Patent Peer reviewed |
|---|---|
| Interventions | 2C-I 2C-B |
| Dose | 25 mg for mild, 50 mg for moderate, 100 mg for severe cases |
| Keywords | Novel therapeutics Sub-hallucinogenic dosing Phenethylamine compounds Chronic disease treatment |
| Citations | 2 |
| Key finding | A method for treating inflammatory or neurological disorders uses subhallucinogenic doses of substituted phenethylamines, with specific doses (25, 50, or 100 mg) based on inflammation severity. |
Abstract
This Patent Highlight presents a method to treat inflammatory or neurological disorders in subjects needing treatment. The method involves administering a therapeutically effective amount of a composition containing a subhallucinogenic concentration of substituted phenethylamine. The substituted phenethylamine may belong to the 2C-X family, including 2C-H, 2C-I, 2C-B, or 2C-E. The specific concentration depends on the chronic inflammation's severity, with 25 mg for mild, 50 mg for moderate, and 100 mg for severe cases.